Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has submitted an application to the U.S. FDA to amend its Phase 3 clinical trial plan for CT-P51, a biosimilar candidate referencing Keytruda.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Application for Amendment of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in the U.S.
- Application Date & Agency: July 6, 2026 (Local Time), U.S. Food and Drug Administration (FDA)
- Clinical Trial Phase: Global Phase 3
- Target Indication: Non-Small Cell Lung Cancer (NSCLC)
- Clinical Trial Title: A double-blind, randomized, active-controlled Phase 3 study to compare the efficacy and safety of CT-P51 versus Keytruda in patients with previously untreated metastatic non-squamous non-small cell lung cancer
- Trial Registration Number: EU CT number 2024-514048-98-00
- Trial Scale & Duration: 220 patients / 2-year treatment period
- Trial Design: Double-blind, randomized, active-controlled
- Board Resolution / Fact Confirmation Date: July 6, 2026
- Investment Caution: Statistically, the final approval rate for clinical drug candidates is approximately 10%. Unforeseen results during trial or approval stages may lead to changes or cancellation of commercialization plans.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 FDA Approval Status and Subsequent R&D Progress Reports
This disclosure pertains to Celltrion’s filing for an amendment to the Phase 3 clinical trial plan for CT-P51 with the U.S. FDA, making it important to monitor the final approval status of the amended plan. Regulatory clearance of the revised protocol is critical for maintaining the intended development timeline, including patient enrollment and dosage schedules. Updates regarding approval and trial progress can be tracked through future follow-up disclosures or the ‘Ongoing Research and Development Activities’ section in periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
